Dare Bioscience, Inc. current report, 21 June 2024

Business context and reporting period

Daré Bioscience, Inc. filed this Form 8-K, reporting a June 21, 2024 event and subsequent actions disclosed through June 27. The filing concerns a charter correction and a planned reverse stock split; it does not report operating or quarterly financial results.

Capital structure and material changes

  • On June 21, the company filed a certificate of correction addressing an inadvertent omission in a 2022 charter amendment that increased authorized common shares from 120 million to 240 million.
  • The board selected a 1-for-12 reverse split, following stockholder authorization for a ratio between 1-for-2 and 1-for-12. The company filed the related charter amendment on June 26.
  • The split was scheduled to take effect at 12:01 a.m. Eastern Time on July 1, 2024, with split-adjusted trading expected to begin that day. The ticker remains DARE; the new CUSIP is 23666P200.
  • The company estimated outstanding common shares would decrease from approximately 101.1 million to approximately 8.4 million. Authorized shares and par value per share remain unchanged.
  • Fractional interests are to be aggregated by holder and rounded up to the next whole share. The filing says ownership percentages and voting power are otherwise unchanged, except for immaterial effects from fractional-share treatment. Outstanding options, warrants, and stock-plan share amounts and exercise prices are to be adjusted proportionately.

Financial metrics, outlook, and risks

The filing provides no revenue, profit, cash flow, margin, debt, or liquidity figures and gives no financial guidance. It does not describe operating changes, contingencies, or a business outlook. The reverse split alone does not establish a change in the company’s underlying financial condition.

Key facts for investors to verify

  • Confirm the reverse split’s effective date and split-adjusted trading commencement.
  • Review the filed charter amendment and certificate of correction for their complete legal terms.
  • Check how the split and related adjustments affect individual share, option, and warrant holdings.
  • Consult subsequent filings for updated share counts and any financial or operating developments.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.